Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Menu

Diamedica Therapeutics Inc (DMAC)

Diamedica Therapeutics Inc (DMAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Best Momentum Stocks to Buy for October 14th
Best Momentum Stocks to Buy for October 14th Zacks Investment Research - Mon Oct 14, 10:02AM CDT

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 14th:IAMGOLD Corporation IAG: This intermediate gold producer has a Zacks Rank #1 and witnessed...

HIVE : 3.13 (-0.32%)
DMAC : 6.41 (+31.62%)
IAG : 5.20 (+2.16%)
New Strong Buy Stocks for October 14th
New Strong Buy Stocks for October 14th Zacks Investment Research - Mon Oct 14, 8:42AM CDT

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:HireQuest, Inc. HQI: This company that provides temporary staffing solutions has seen the Zacks Consensus Estimate for its current...

HIVE : 3.13 (-0.32%)
HQI : 14.31 (+2.14%)
CLPR : 5.80 (-3.33%)
DMAC : 6.41 (+31.62%)
IAG : 5.20 (+2.16%)
Author
Three (3) Stocks Under $10 That Insiders Are Buying  MarketBeat - Wed Jul 5, 2023

These small-cap names provide an opportunity that insiders are buying including deep value, growth, new technology, and AI.

DMAC : 6.41 (+31.62%)
ADT : 6.83 (+0.59%)
CMTL : 3.69 (+22.59%)
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023 Business Wire - Mon May 8, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today...

DMAC : 6.41 (+31.62%)
DiaMedica Therapeutics Appoints David Wambeke as Chief Business Officer Business Wire - Tue Apr 11, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for acute ischemic stroke (AIS), today announced the appointment of David...

DMAC : 6.41 (+31.62%)
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2022 Financial Results Business Wire - Tue Mar 28, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...

DMAC : 6.41 (+31.62%)
DiaMedica Therapeutics to Report Fourth Quarter 2023 Financial Results and Provide a Business Update March 29, 2023 Business Wire - Mon Mar 20, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today...

DMAC : 6.41 (+31.62%)
DiaMedica Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference Business Wire - Mon Mar 13, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today announced that Rick Pauls,...

DMAC : 6.41 (+31.62%)
DiaMedica Therapeutics Announces the Appointment of Biopharma Veteran Tanya Lewis to Its Board of Directors Business Wire - Mon Mar 6, 2023

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, announced today the appointment...

DMAC : 6.41 (+31.62%)
KPTI : 0.6350 (-2.25%)
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2022 Financial Results Business Wire - Wed Nov 9, 2022

DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and kidney diseases, today provided a business update...

DMAC : 6.41 (+31.62%)

Barchart Exclusives

Scalp a 47% Payout by the End of This Week with Micron (MU) Call Spreads Barchart - Sat Dec 21, 9:15AM CST
Yes, there are serious questions about MU stock following the underlying company’s disappointing earnings but a steady march is all options traders need. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot